Ambu A/S: expands access to over a million procedures in the ENT segment

Ambu Expands Access to Over One Million Procedures in the ENT Segment

Ambu expands its addressable market by supporting FEES procedures.

Ambu continues to advance the single-use endoscopy market by addressing fiberoptic swallowing endoscopic assessment (FEES). FEES is an imaging procedure that requires the use of a flexible nasolaryngoscope to assess swallowing physiology and function in people who experience difficulty swallowing (dysphagia). In the ENT (ear, nose and throat) segment, the FEES procedure typically enjoys much higher reimbursement from healthcare systems, which is a key driver for the adoption of single-use endoscopes.

With new FEES capabilities, the aScope™ 4 RhinoLaryngo Slim and aView™ 2 Advance HD single-use monitors form a portable solution that improves workflow for clinicians performing bedside FEES in intensive care units, hospitals treatment rooms and acute care facilities.

Overall, I find that using the Ambu Rhinolaryngoscope has improved the experience of fiberoptic swallow assessments for the clinician and the patient. For me, the scope is light, easy to use and always available. For the patient, there is comfort due to the endoscope’s thin diameter and no risk of cross-contamination from an endoscope that may not have been reprocessed properly.” says Jacqueline Mojica1MS, CCC/SLP, Clinical Specialist, Speech Pathology, Assistant Clinical Professor, NYU Langone Medical Center, New York.

More than one million FEES procedures are performed each year in Ambu’s major markets in North America, Europe and Asia Pacific.

FEES procedures represent a large and growing area for patient care, an area that has become even more important since Covid-19, and an area where single-use endoscopy can play an important role,” says Bassel Rifai, Marketing Director at Ambu A/S. “We are excited to support healthcare systems with this expanded capability, and this represents another example of how Ambu is expanding the market for single-use endoscopy.

Ambu launched its first single-use rhinolaryngoscope in 2018 to enter the ENT market. With the FEES capability, Ambu further extends its leading position in the field of single-use ENT endoscopy. This will be followed by the launch of high resolution nasolaryngoscopes in the future.

contacts

Media

Mikkel Trier Wagner, Director, Corporate Communications,[email protected]/ +45 4191 0830

Investors

Nicolai Thomsen, Director, Investor Relations and Strategic Financial Planning,[email protected]/ +45 2620 8047

1 Dr. Mojica is a paid consultant to Ambu A/S. She was not compensated for her quote in this press release.

Ambu A/S

Baltorpbakken 13, DK-2750 Ballerup, Denmark, Tel. : +45 7225 2000, CVR number: 63 64 49 19,www.ambu.com

About Ambu

Ambu has been bringing the solutions of the future to life since 1937. Today, millions of patients and healthcare professionals around the world depend on the efficiency, safety and performance of our solutions for endoscopy, anesthesia and disposable patient monitoring device. We are constantly looking to the future with a commitment to providing quality, innovative products that have a positive impact on patient care and the work of healthcare professionals. Based near Copenhagen in Denmark, Ambu employs around 4,500 people in Europe, North America and Asia-Pacific. For more information, please visit ambu.com or ambuUSA.com or follow us on our LinkedIn company and United States LinkedIn pages.

Comments are closed.